In postpartum dairy cows, compounded florfenicol uterine infusions are prepared at 20 mg/mL nominal concentration because aqueous solubility of the unesterified API is limited to approximately 1.32 mg/mL at 25 °C. A 316L stainless steel jacketed vessel with bottom-sweep agitation is charged with water for injection, and a suspending carrier is hydrated—hypromellose 0.5% w/v plus poloxamer 188 0.1% w/v—before the API is dispersed under a rotor-stator homogenizer at 3,000 rpm for 10 min. pH adjustment with phosphate buffer to 6.5–7.0 reduces mucosal irritation, but moving pH toward 7.4 further depresses the already low solubility. Terminal moist-heat sterilization at 121 °C for 15 min is acceptable only if the polymer system does not undergo thermal gelation; otherwise the preparation is filtered through a 5 μm capsule filter as a non-sterile uterine suspension under veterinary direction. Documentation for extemporaneous compounding follows USP <795>, and if sterile filtration is claimed, USP <797> engineering controls apply. VICH GL18 residual-solvent limits apply when organic cosolvents are introduced. Published large-scale clinical outcome data for this specific compounded configuration are limited, so batch records must capture particle size, sedimentation behavior, and osmolality at release.

The dominant source of batch-to-batch variance is API particle size, not mixing time. A milled D90 exceeding 25 μm commonly produces visible settling within 1 h, while a D90 below 10 μm can maintain redispersibility for up to 6 h under intermittent agitation. The suspension is filled into 100 mL amber type II glass vials with butyl rubber closures. In-use stability after first opening is assigned under VICH GL3 at 25 °C/<60% RH and 5 °C for 7 days; beyond this period, resuspendability and microbiological quality may decline. Moisture content of the dried API prior to dispersion is controlled below 0.5% by USP <921>. Oxidizing agents and strong alkaline buffers are avoided because the methylsulfonyl and dichloroacetamide groups may degrade under oxidative or strongly alkaline conditions.

What Solvent System Prevents Florfenicol Precipitation in Injectable Concentrates?

For injectable concentrates at 300 mg/mL, florfenicol is formulated in non-aqueous aprotic solvent blends because the aqueous solubility of the base is 1.32 mg/mL at 25 °C. A binary solvent system of 2-pyrrolidone and propylene glycol is typical; when 2-pyrrolidone falls below 20% v/v, recrystallization can occur after 48 h at 4 °C. In a 200 L glass-lined vessel, the solvents are heated to 35 °C before micronized florfenicol is added under 500 rpm agitation. Tip speed is maintained above 1.5 m/s; lower tip speed can create unmixed solvent pockets and promote crystal growth. The finished solution is cooled to 25 °C and filtered through a 0.22 μm PVDF cartridge. Viscosity at 25 °C is typically 25–45 mPa·s; readings above this range reduce filter throughput and complicate filling-line nozzle drip control. The approved injectable reference for bovine respiratory disease associated with Mannheimia haemolytica, Pasteurella multocida, and Histophilus somni is 21 CFR 522.955. USP <788> particulate-matter limits apply to the filtered solution.

Cold-chain logistics are not normally required, but the ternary solvent system can undergo phase separation when propylene glycol exceeds 45% v/v and the product is held at 2 °C for more than 48 h. Water uptake is controlled below 0.1% by Karl Fischer titration; residual water above 0.3% w/w causes turbidity and supports hydrolytic degradation. Filling under nitrogen overlay reduces dissolved oxygen below 1 mg/L. In-use stability is validated according to VICH GL3 at 25 °C and 4 °C; the 4 °C condition is significant because product is frequently stored in farm refrigerators. The injectable solution is administered undiluted because aqueous dilution at the point of administration can cause immediate precipitation. Needle size is determined by injection site and animal size, commonly 18-gauge or larger for subcutaneous or intramuscular administration in adult cattle.

When Florfenicol Premix Granulation Exceeds 60 °C

During high-shear wet granulation of swine feed premixes, dry blending alone may fail USP <905> blend uniformity because raw florfenicol API has poor flow and tends to segregate in low-dose premixes. The API is first milled to D90 below 75 μm and dry-blended with lactose monohydrate and microcrystalline cellulose in a 500 L high-shear granulator. Water is sprayed at 8–12% w/w over 3–5 min while impeller speed is kept at 250 rpm and chopper speed at 3,000 rpm. Wet massing is limited to 3 min; extended massing densifies the granule and can retard subsequent drug release. The wet granules are dried in a fluid-bed dryer with inlet air temperature not exceeding 60 °C, because case hardening above this temperature can trap residual moisture inside granules and generate assay variability in the finished premix. Final moisture is controlled below 2.0% using USP <921>.

Dried granules are milled through a 1.0 mm screen, blended with colloidal silicon dioxide 0.5% w/w and magnesium stearate 0.25% w/w, and packed into 25 kg multi-wall paper bags with polyethylene liners. At the feed mill, the premix is diluted in a ribbon blender with 10 min mixing at 70% nominal capacity. Overfilling above 80% capacity reduces mixing uniformity; underfilling below 40% may create dead zones. The following release criteria are applied to the granulated premix before feed dilution:

Stability of the granulated premix is evaluated under VICH GL3 accelerated storage at 40 °C/75% RH for 6 months; assay loss greater than 5% triggers long-term confirmatory testing. Where feed-grade regulatory approval exists, final medicated feed must comply with 21 CFR Part 558 or corresponding local medicated feed rules.

When drinking-water powders are prepared for broilers and turkeys, the finished powder is not a true solution at label doses; the base API dissolves at approximately 1.32 mg/mL in water at 25 °C, so line distribution depends on dispersed low-micron particles. The dry powder is manufactured by blending florfenicol with maltodextrin and sodium lauryl sulfate 0.2% w/w as a wetting agent, then wet granulating or compacting with an isopropanol-based binder. Residual isopropanol is limited by VICH GL18 and measured by headspace gas chromatography. The granulate is milled through a 0.5 mm screen; D90 after dispersion is specified below 50 μm to prevent nipple-drinker occlusion. Field water hardness above 250 mg/L calcium carbonate can reduce dispersability because anionic wetting agents complex with divalent cations; in such water, nonionic wetting systems are preferable to anionic surfactants.

The diluted stock solution is metered into drinking lines at 1:1000 proportioning to deliver 20 mg/kg body weight per day over the required treatment period. The final dispersion should be consumed within 24 h after mixing; beyond 24 h, settling and biofilm growth in header tanks can lower the delivered dose below target. In-use stability is validated under VICH GL3 at 25 °C and 60% RH for 24 h with assay loss not more than 5% and redispersibility after 10 inversions. Free chlorine at 2–4 ppm in municipal drinking water is not known to immediately inactivate florfenicol, but published data on all water matrices are limited; verification in the specific farm water source is required before release of the in-use protocol.

Aquaculture Premix Dispersibility and Gastric Retention in Freshwater Species

After extrusion and vacuum coating, florfenicol premixes for farmed finfish are applied at 10 mg/kg biomass per day for 10 consecutive days where authorized. The medication is incorporated after wet extrusion rather than before, because aqueous extrusion and barrel temperatures above 105 °C can reduce recovery, and post-extrusion vacuum coating preserves surface-associated drug from wash-off. A vacuum coater operating at −0.8 bar coats pellets with fish oil containing suspended florfenicol; the oil phase is sprayed at 0.5 bar to achieve 2% w/w oil uptake. Fine particle control is significant because fines smaller than 0.5 mm sink or remain suspended and are not consumed by fish, reducing actual dose. Sieve analysis after coating should show not more than 2% w/w fines passing a 0.5 mm screen.

Leaching from finished pellets is evaluated by static immersion in water at 25 °C for 30 min; a design target of ≥90% label claim retention in the pellet after immersion is used. Pellet hardness is balanced against water stability; excessively hard pellets reduce gastric retention in species such as tilapia, while soft pellets disintegrate and release the drug into the water column. Premix assay is verified by HPLC per Ph. Eur. 2.2.29, and blend uniformity is verified by USP <905>. Where fish feed applications are regulated, 21 CFR Part 558 or equivalent national medicated feed rules apply. Solvent residues from coating oils are limited by VICH GL18. Uncoated mash use is associated with substantial wash-off losses, and aqueous medication of pond water is not a reliable route.

Tablet Hardness above 10 kp Delays Disintegration in Small Ruminant Doses

If tablet hardness exceeds 10 kp, disintegration can extend beyond 30 min in compounded small-ruminant formulations. Raw florfenicol is roll-compacted rather than directly compressed because bulk density is below 0.4 g/mL and powder flow is erratic on rotary tablet presses. Roller compaction with microcrystalline cellulose PH102 and croscarmellose sodium 2.0% w/w at 12 kN/cm roll force, followed by milling through a 1.0 mm screen, raises bulk density to approximately 0.6 g/mL. Tablets compressed to 5–8 kp hardness disintegrate within 15 min in water at 37 °C using USP <701>. If hardness is raised above 10 kp to reduce friability, the resulting delay in disintegration slows dissolution in 900 mL of 0.1 N HCl at 50 rpm using USP <711> Apparatus 2.

Capsule filling avoids the hardness-disintegration conflict but requires tight control of D90 below 150 μm and magnesium stearate below 0.5% w/w, because hydrophobic lubricant overlubrication retards wetting. Fill weight variation is monitored by USP <905>; dissolution method transfer uses USP <711> with 900 mL of 0.1 N HCl at 37 °C ± 0.5 °C. Published dissolution specifications for florfenicol tablets and capsules of veterinary origin are not harmonized; each batch release is therefore based on site-specific validated methods. Compounded use in small ruminants is outside approved label in many jurisdictions, and published residue depletion data for this configuration are limited. These tablets should not be combined with antacids containing magnesium trisilicate, which raises gastric pH and can alter the dissolution rate.